Cargando…
Therapeutic Immunization against Glioblastoma
Glioblastoma is the most common form of brain cancer in adults that produces severe damage to the brain leading to a very poor survival prognosis. The standard of care for glioblastoma is usually surgery, as well as radiotherapy followed by systemic temozolomide chemotherapy, resulting in a median s...
Autores principales: | Schijns, Virgil E. J. C., Pretto, Chrystel, Strik, Anna M., Gloudemans-Rijkers, Rianne, Devillers, Laurent, Pierre, Denis, Chung, Jinah, Dandekar, Manisha, Carrillo, Jose A., Kong, Xiao-Tang, Fu, Beverly D., Hsu, Frank P. K., Hofman, Florence M., Chen, Thomas C., Zidovetzki, Raphael, Bota, Daniela A., Stathopoulos, Apostolos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163986/ https://www.ncbi.nlm.nih.gov/pubmed/30150597 http://dx.doi.org/10.3390/ijms19092540 |
Ejemplares similares
-
Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4(+) T-lymphocyte counts
por: Bota, Daniela A, et al.
Publicado: (2018) -
First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity
por: Schijns, Virgil E.J.C., et al.
Publicado: (2015) -
Development of immune memory to glial brain tumors after tumor regression induced by immunotherapeutic Toll-like receptor 7/8 activation
por: Stathopoulos, Apostolis, et al.
Publicado: (2012) -
Exploring the Therapeutic Efficacy of Glioma Vaccines Based on Allo- and Syngeneic Antigens and Distinct Immunological Costimulation Activators
por: Stathopoulos, Apostolos, et al.
Publicado: (2012) -
A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and Temozolomide
por: Bota, Daniela A., et al.
Publicado: (2022)